

2018 CANM-CAMRT Joint Annual Conference

Overall objectives of the conference:

1. Maintain competence on a wide variety of up-to-date topics in Nuclear Medicine
2. Discuss hot new topics
3. Establish a network of Nuclear Medicine specialists
4. Promote Nuclear Medicine as a specialty

Please note that 25% of allowed time to each speaker will be reserved for questions from participants.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program (MOC) of the Royal College of Physicians and Surgeons of Canada and approved by the Continuing Professional Development Directorate (CPDD) of the Fédération des médecins spécialistes du Québec.

You may claim up to 20 hours for this activity (credits are automatically calculated in MAINPORT). Participation in this activity qualifies for a certificate of attendance. Participants should claim a number of hours consistent with their attendance.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

La présente activité est une activité d'apprentissage collectif agréée (section 1), au sens que lui donne le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada; elle a été approuvée par la direction du Développement professionnel continu de la Fédération des médecins spécialistes du Québec.

Vous pouvez déclarer un maximum de 20 heures (les crédits sont calculés automatiquement dans MAINPORT). Une participation à cette activité donne droit à une attestation de présence. Les participants doivent réclamer un nombre d'heures conforme à la durée de leur participation.

En vertu d'une entente conclue entre le Collège royal des médecins et chirurgiens du Canada et l'American Medical Association (AMA), les médecins peuvent convertir les crédits obtenus au titre du programme de MDC du Collège royal en crédits de catégorie 1 de l'AMA PRAMC. Vous trouverez l'information sur le processus de conversion des crédits du programme de MDC du Collège royal en crédits de l'AMA à l'adresse www.ama-assn.org/go/internationalcme.

CAMRT / ACTRM

CATEGORY A CREDIT

Session attendance will be tracked with personalized attendance sheets. This provides the CAMRT with an accurate record of each MRT's attendance at individual educational sessions. To receive credit for the sessions attended, the participant must have their attendance sheet stamped when entering and leaving the session. Credit will only be assigned to sessions attended in full. Participants arriving late to the session or leaving early will not have their attendance sheet stamped and will not receive the assigned credit. There will be a "5-minute grace period" at the **beginning** of each session.

Category A credit hours have been pre-assigned to all educational* sessions. One credit is equivalent to one hour of education. MRTs may use these credits (hours) to fulfill CE requirements established by a professional association or regulatory body. The CAMRT is a Recognized Continuing Education Evaluation Mechanism (RCEEM) for the American Registry of Radiologic Technologists (ARRT) therefore allowing participants attending from the United States and Canadians who have an active ARRT membership to use these credits to fulfill their biennium requirements.

Records of attendance will be provided electronically to the email address provided on the attendance sheet by end of April 2018.

**To qualify as educational, an activity must provide sufficient depth and scope of a subject area. Business meetings, poster and exhibit viewing, social events, etc., do not qualify for credit.*

CRÉDITS DE CATÉGORIE « A »

La présence aux séances sera enregistrée au moyen de fiches de présence personnalisées, ce qui fournit à l'ACTRM un relevé précis de la présence de chaque TRM à chaque séance de formation. Pour recevoir les crédits rattachés à chaque séance, le participant doit faire timbrer sa fiche de présence à l'entrée et à la sortie de la salle. Les crédits ne seront accordés que pour les séances auxquelles le participant est présent en entier. Les participants qui arrivent en retard à la séance ou qui partent avant la fin ne pourront pas faire timbrer leur fiche de présence et ne recevront pas les crédits accordés. Il y aura une « période de grâce » de cinq minutes **au début** de chaque séance.

Des heures de crédits de catégorie « A » ont été attribuées à l'avance à chacune des séances éducatives*. Un crédit correspond à une heure de formation. Les TRM peuvent utiliser ces crédits (heures) pour satisfaire aux exigences de formation continue établies par une association professionnelle ou par un organisme de réglementation. L'ACTRM a le statut de Mécanisme d'évaluation de la formation continue reconnu (RCEEM) pour l'American Registry of Radiologic Technologists (ARRT), ce qui permet aux participants des États-Unis et aux Canadiens qui sont membres actifs de l'ARRT d'utiliser ces crédits pour satisfaire à leurs obligations biennales. **Les dossiers de présence** seront transmis électroniquement à l'adresse de courriel indiquée sur la fiche de présence avant la fin d'avril 2018.

**Pour être admissible à titre d'activité éducative, une activité doit examiner un sujet de façon suffisamment approfondie et étendue. Les rencontres d'affaires, les expositions d'affiches, les activités sociales, etc. ne sont pas admissibles à des crédits.*

2018 CANM-CAMRT Joint Annual Conference

THURSDAY, MARCH 22, 2018

0800 - 1200	CANM Board Meeting (closed)	<i>Prospect</i>
0800 - 1500	Exhibits Set-up	<i>Salon 1 & Stanley Park Foyer</i>
1200 - 1700	REGISTRATION	<i>Stanley Park Foyer</i>
1300 - 1730	HEALTH ECONOMICS, TECHNOLOGY ASSESSMENT & NM VALUE SYMPOSIUM	<i>Salon 3</i>
1300-1430	Early Afternoon Session Chairs: Norman Laurin/Karren Fader	
	<ol style="list-style-type: none"> 1. Framing the Session: The Canadian “Landscape” Norman Laurin <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Highlight the difficulties facing access to old and new radiopharmaceuticals in Canada.</i> • <i>Highlight the hurdles facing the introduction of new equipment and imaging procedures, including the differences between Canadian Provinces, and difficulties in defining their value.</i> • <i>Illustrate the growing gap between nuclear medicine in Europe versus the rest of the world.</i> 2. CIHI: Health Care Spending Michael Hunt <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Understanding comparative expenditure data at the provincial/territorial and international levels, as well as Canadian health spending trends from 1975 to the present.</i> 3. CADTH: Health Technology Assessment Harindra Wijeyesundera <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Define and review the life-cycle of health technologies.</i> • <i>Recognize when and how health technology assessments are made.</i> • <i>Illustrate the definition of "value" in medical devices.</i> 	
1430-1500	REFRESHMENT BREAK	
1500-1630	Mid Afternoon Session Chairs: Jean-Luc Urbain/François Couillard	
	<ol style="list-style-type: none"> 4. The Values of Global Access to Radiation Therapy Danielle Rodin <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Define global access to radiation therapy</i> • <i>Review the processes involved in the global access to radiation therapy</i> • <i>Explain the advantages the global access to radiation therapy.</i> 	

5. PET/CT Value: The Rocky Mountain Cancers Centers Perspectives

Glenn Balasky

Objectives:

- Analyze PET/CT utilization in a large oncology practice.
- Define the Clinical indications in an oncology practice.
- Describe the proper Management of PET/CT to assure proper utilization

6. Nuclear Medicine Value Seen by a Nuclear Medicine Professional

Bennett Greenspan

Objectives:

- Discuss how Nuclear Medicine/Molecular Imaging brings value to imaging practice by providing research and development resulting in new radiotracers approved for routine clinical practice.
- Discuss how Nuclear Medicine brings value in Oncology with the use of radionuclide therapy, which is providing improved patient outcomes with much less morbidity and cost.

7. Conclusion: The Tasks Ahead of the NM Community

François Couillard

Objectives:

- Identify the challenges ahead for Nuclear Medicine in a context of healthcare cost constraints and competing modalities.
- Propose initiatives to ensure Nuclear Medicine remains a modality at the forefront of healthcare innovation.

1630-1730

Panel Discussion

Chairs: Jean-Luc Urbain/Karren Fader

- Define the various components/parameters that need to be taken into consideration while evaluating the value of nuclear medicine tests
- Discuss the priorities to focus on to establish nuclear medicine tests as an integral part of the patients care continuum

1800 - 1900

Welcome Reception with Exhibitors

Salon 1 & Stanley Park Foyer

1915 - 2200

CANM Industry Forum (closed)

Oak Room

1915 - 2200

CANM Residents' Forum (for residents only)

Salon 3

Facilitators: Denise Chan & Salem Yuoness

1915-1930

Welcome

Andrew Ross, CANM President

1930-1945

Exam Planning

Andrew Ross, Halifax, Nova Scotia

1945-2000

Career Planning and Advice - Maritimes

Jeffrey Flemming, St. John's, Newfoundland

2000-2015

Career Planning and Advice – British Columbia

Pete Tonseth, Vancouver, BC

2015-2030

Career Planning and Advice – Alberta

Amar Suchak, Calgary, AB

2030-2045

Career Planning and Advice – Québec

Khun Visith Keu, Montréal, Québec

2045-2100

Career Planning and Advice – Ontario

Christopher O'Brien, Brantford, Ontario

2100-ON

Discussion

FRIDAY, MARCH 23, 2018

0700 - 1700	REGISTRATION	<i>Stanley Park Foyer</i>
0700 - 0800	CONTINENTAL BREAKFAST	<i>Salons 1, 2 & 3</i>
0700 - 1700	EXHIBITS CONTINUE	<i>Salon 1 & Stanley Park Foyer</i>
0700 - 1700	POSTERS SET-UP	<i>Stanley Park Foyer</i>
0745 - 0800	WELCOME Jean-Luc Urbain & Karren Fader	<i>Salons 2 & 3</i>

0800 - 1215	SESSION 1 - RADIONUCLIDE THERAPY/THERANOSTICS	<i>Salons 2 & 3</i>
--------------------	--	-------------------------

RADIONUCLIDE THERAPY

Chairs: Philip Cohen/Karren Fader

0800-0830	Experience Using Homogeneous Sn-117m Colloid for RSO Cynthia Doerr <i>Objectives:</i> <ul style="list-style-type: none"> • Describe the new isotope, Sn-117m, currently in clinical trial preparation for use in human RSO. • Explain the advantages of Sn-117m homogeneous colloid vs Y-90 and Re-186 for RSO. • Review the therapeutic mechanism-of-action of a long half-life isotope in a stable colloid.
0830-0900	Rhenium 188: Epidermal Radioisotope Therapy Philip Cohen <i>Objectives:</i> <ul style="list-style-type: none"> • Describe the Re-188 advantages as a radionuclide therapy. • Review the use of Re-188 in treating skin cancer. • Explain the advantages and disadvantages of Re-188 therapy for skin cancer.
0900-0930	Radiation Safety in Sentinel Node Imaging Samantha Jackson <i>Objectives:</i> <ul style="list-style-type: none"> • Review the radiopharmaceutical used and injection techniques involved in Sentinel Node procedures. • Recognize the areas where contamination may occur and discuss preventative measures. • Discuss Radiation safety of all personal involved.

PROSTATE CANCER

Chairs: Joseph Cortese/Christiaan Schiepers

0930-0945	Patient Considerations in a PSMA PET/CT Trial Nav Jabal <i>Objectives:</i> <ul style="list-style-type: none"> • Describe the Indication and Enrollment Process for patients in the PSMA PET/CT Trial. • Describe Patient Set up and Imaging Parameters in a 18F-DCFPyl PSMA Scan. • Identify Normal and Abnormal uptake in a 18F-DCFPyl PSMA scan.
------------------	--

	<p>0945-1000 Chemo and Hormonal Considerations for Prostate Cancer Krista Noonan</p> <ul style="list-style-type: none">• Review the medical therapeutic options for prostate cancer• Identify the proper indications for the medical therapies that are currently available. <p>1000-1030 RN Diagnosis & Treatment Christiaan Schiepers Objectives:</p> <ul style="list-style-type: none">• Explain the principle of personalized theranostics with radioligands in prostate cancer.• Discuss the UCLA experience in PSMA imaging and therapy.
1030-1045	REFRESHMENT BREAK Salon 1 & Stanley Park Foyer
	NM: A PATIENT-CENTERED JOURNEY Chairs: Karren Fader/Louise Rimanic
	<p>1045-1110 How PET and the Personal Onco-Genomic (POG) Trial are Able to Create Patient-Centered Care Howard Lim Objectives:</p> <ul style="list-style-type: none">• Understand the use of genomic based testing in oncology• Examine the use of PET for genomic based testing• Review the pitfalls of genomic based testing <p>1110-1125 My Experience with POG Zuri Scrivens</p> <p>1125-1145 An MRT Shares Her Experience: When the Provider is Now the Patient Louise Rimanic Objectives:</p> <ul style="list-style-type: none">• Utilizing best practice to optimize the patient's experience.• Recognize the importance of practicing excellence.• Identify methods to improve time management and reduce patient anxiety. <p>1145-1215 Preparing Health Professionals for the Challenges of Caring for the Oncology Patient Megan Murphy & McKenzie Ricard Objectives - McKenzie Ricard:</p> <ul style="list-style-type: none">• Describe a personal experience in the health care field.• Illustrate the major challenges faced and how to cope with them and how to prevent them <p>Objectives - Megan Murphy:</p> <ul style="list-style-type: none">• Participants will be able to recognize the importance of empathy and interpersonal communication skill development in healthcare education.• Participants will be able to describe common interpersonal challenges faced by new nuclear medicine technologists.• Participants will be able to identify at least three ways to support the continued interpersonal skill development of healthcare professionals.

1215 - 1315 LUNCHEON

Salons 1, 2 & 3

1315 - 1445 SESSION 2 - CARDIOLOGY

Salons 2 & 3

QUANTIFICATION OF CORONARY FLOW RESERVE

Chairs: Thomas Wong/Matthieu Pelletier-Galarneau

1315-1330 Physiology of Coronary Circulation

Raymond Russel

Objectives:

- Identify the components of the coronary circulation.
- Describe the effects of the cardiac cycle on coronary flow.
- Describe the effects of vasodilation on coronary flow.

1330-1345 Methods of Evaluation of Coronary Circulation

Raymond Russel

Objectives:

- Identify the methods for invasive assessment of coronary flow.
- Describe the non-invasive methods to evaluate coronary flow.
- Review the radionuclide-based methods of coronary flow assessment.

1345-1405 Image Enhancement of Myocardial SPECT Studies

Thomas Wong

Objectives:

- Identify technical differences between SPECT quantification of myocardial flow reserve and traditional myocardial perfusion SPECT.
- Describe the technologist's role in optimizing image quality of myocardial SPECT studies.
- Apply common processing techniques to help optimize SPECT image quality.

1405-1425 PET Evaluation

Matthieu Pelletier-Galarneau

Objectives:

- Detail and explain how myocardial blood flow is measured with PET/CT.
- Review the value of absolute myocardial blood flow quantification and coronary flow reserve (CFR).
- Advise on how to integrate flow quantification in imaging interpretation.

1425-1445 SPECT Evaluation

Raymond Russel

Objectives:

- Compare the differences in SPECT-based perfusion tracers.
- Describe the quantification of SPECT perfusion defects.
- Recognize high risk features in a SPECT myocardial perfusion study.

1445-1500 REFRESHMENT BREAK

Salon 1 & Stanley Park Foyer

1500 -1540 AWARDS & ABSTRACTS PRESENTATIONS

Salons 2 & 3

Chairs: Karren Fader/Matthieu Pelletier-Galarneau

ERIC LEPP COMPETITION WINNER PRESENTATION**1500-1508** Complete Resolution of Myocardial Inflammation Related to Biopsy-Proven Cardiac-Limited Sarcoidosis on Serial 18f-FDG PET Scans – *Caroline Malo Pilon (EL-002)***SELECTED ABSTRACTS ORAL PRESENTATIONS****1508-1516** F-18 FDG Labeling of Human White Blood Cells - *Ashley Mummery (023)*

- 1516-1524** The Canadian Medical Imaging Inventory (CMII): Benefits for Decision-Makers - *Andra Morrison (018)*
- 1524-1532** Diagnosis of Pulmonary Embolism in the Canadian Context: Clinical Review Findings from A Health Technology Assessment – *Sarah Garland (021)*
- 1532-1540** Comparison of FRAX and CAROC Fracture Risk Assessment Tools - *Jamie Grandy (011)*

1540-1700	SESSION 3 - PEDIATRICS	<i>Salons 2 & 3</i>
------------------	-------------------------------	-------------------------

NUCLEAR MEDICINE PROCEDURES IN CHILDREN

Chairs: Louise Rimanic /Helen Nadel

1540-1550	<p>The Impact of CZT on Pediatric Imaging Wendy Anderton <i>Objectives:</i></p> <ul style="list-style-type: none"> • <i>Characterize and illustrate the incorporation of a CZT camera into a NM pediatric practice and its impact on workflow, the study procedures and pediatric patient care.</i>
1550-1625	<p>Indication for SPECT/CT Studies Daniel Levin <i>Objectives:</i></p> <ul style="list-style-type: none"> • <i>Introduce bone and soft tissue indications for SPECT/CT in children.</i> • <i>Describe the utility of SPECT/CT in this patient population.</i>
1625-1700	<p>Indications for PET/CT Studies Helen Nadel <i>Objectives:</i></p> <ul style="list-style-type: none"> • <i>List indications and methods to optimize PET/CT in pediatric patient management.</i> • <i>Describe current use of PET/CT in tumour response assessment in common pediatric tumors.</i> • <i>Suggest potential future role of PET/CT in personalized medicine.</i>

1700-1730	CANM AGM	<i>Salons 2 & 3</i>
------------------	-----------------	-------------------------

1900-1945	POSTERS PRESENTATIONS & REVIEWS with RECEPTION	<i>Stanley Park Foyer</i>
------------------	---	---------------------------

1945-2130	<p>AWARDS DINNER CANM Awards Presentations: Residents' Travel Awards - Ashley Mummery, Guillaume Chaussé, Peter George Maliha CANM 2018 Eric Lepp Award - Caroline Malo Pion CANM Emeritus Member 2018 – John Powe</p>	<i>Salons 2 & 3</i>
------------------	--	-------------------------

SATURDAY, MARCH 24, 2018

0730 - 1000	REGISTRATION	<i>Stanley Park Foyer</i>
--------------------	---------------------	---------------------------

0730 - 0830	<p>SUNRISE SYMPOSIUM WITH BREAKFAST Chair: Tom Pickles Treating the NHL of Cancers: How to Score In Indolent With Radioimmunotherapy Neil Berinstein</p> <ul style="list-style-type: none"> • <i>Inform on the current Management of Indolent Lymphoma</i> • <i>Review the effects of ⁹⁰Yttrium Ibritumomab Tiuxetan indolent lymphoma</i> • <i>Describe the results of the Phase II trial of ⁹⁰Yttrium Ibritumomab Tiuxetan in high risk follicular lymphoma.</i> 	Salons 2 & 3
0730 - 1630	EXHIBITS CONTINUE	Salon 1 & Stanley Park Foyer
0730 - 1630	POSTERS	Stanley Park Foyer
0830 - 1000	<p>SESSION 4 - BRAIN IMAGING Chairs: Reza Berenji/Rhonda Hollerbaum</p>	Salons 2 & 3
SPECT IMAGING		
0830-0845	<p>Imaging Challenges in Brain SPECT Dara Barrett Objectives:</p> <ul style="list-style-type: none"> • <i>Utilize support systems.</i> • <i>Identify the patient's needs pertaining to the exam.</i> • <i>Apply similar techniques to all patient exams.</i> 	
0845-0915	<p>Clinical Indications Theodore Henderson Objectives:</p> <ul style="list-style-type: none"> • <i>Recognize that perfusion SPECT neuroimaging has modern applications.</i> • <i>Identify and specify sensitivity and specificity in differentiating dementia types.</i> • <i>Understand data supporting neuropsychiatric applications of perfusion SPECT neuroimaging.</i> 	
PET IMAGING		
0915-0930	<p>Adapting Practice for Quality PET/CT Brain Imaging Caroline Williams Objectives:</p> <ul style="list-style-type: none"> • <i>To review clinical indications that can affect brain imaging.</i> • <i>To help guide patient positioning using alternative methods.</i> • <i>To learn how to reduce image artifacts.</i> 	
0930-1000	<p>Clinical Indications Reza Berenji Objectives:</p> <ul style="list-style-type: none"> • <i>PET application in Epilepsy.</i> • <i>PET application in Dementia.</i> • <i>PET application in Brain Tumors.</i> 	
1000 - 1030	REFRESHMENT BREAK	Salon 1 & Stanley Park Foyer

1030- 1145	SESSION 5 - LUNG SCINTIGRAPHY	<i>Salons 2 & 3</i>
Chairs: Rhonda Hollerbaum /Norman Laurin		
1030-1045	Patient Dose in the Diagnosis of PE Izaaz Badshah <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Inform on the types and doses of radiopharmaceuticals use for the diagnosis of PE.</i> • <i>Know when to order each test.</i> 	
1045-1105	The Diagnosis of PE in the Choosing Wisely Era Norman Laurin <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Review and analyze the strength and limitations of V/P scintigraphy and CTPA in PE investigation.</i> • <i>Describe the appropriate medical indications for V/Q</i> 	
1105-1125	PE Was Diagnosed Then What? Jean-Luc Urbain <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Illustrate the various anticoagulation therapeutic options used for PEs.</i> • <i>Review the current protocols used for the treatment of PEs.</i> • <i>Discuss the effectiveness of anticoagulation therapies in PEs</i> 	
1125-1145	Is There Any Other Indication for VQ Scan? Andrew Ross <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Describe the properties of the Technegas ventilation system for the V/Q scans</i> • <i>Review the new V/Q scans applications in respiratory pathology such as COPD.</i> 	
1145-1300	LUNCHEON SYMPOSIUM Chair: Jean-Luc Urbain Adding Value to Your Practice with Dopamine Transporter Imaging Philip Kuo <i>Objectives:</i> <ul style="list-style-type: none"> • <i>Supervise key aspects for the proper performance of dopamine transporter SPECT Imaging.</i> • <i>Review the anatomic and physiologic for accurate interpretation.</i> • <i>Identify pitfalls of performance and interpretation.</i> 	<i>Salons 1, 2 & 3</i>
1300 -1445	SESSION 6 - CT REVIEW COURSE	<i>Salons 2 & 3</i>
Chairs: Rustain Morgan/Joseph Cortese		
1300-1315	Dose Optimization in CT Bryce Gillman <ul style="list-style-type: none"> • <i>Summarize various factors that influence radiation dose from CT.</i> • <i>Describe strategies for CT dose optimization.</i> • <i>Evaluate your departments current CT parameters.</i> 	

	<p>1315-1400</p> <p>1400-1445</p>	<p>SPECT/CT Study Rustain Morgan & Heather Hughes <i>Objectives – Heather Hughes:</i></p> <ul style="list-style-type: none"> To list the indications for commonly performed diagnostic SPECT/CT scans. To describe the advantages of performing a hybrid diagnostic SPECT/CT scan over SPECT or CT alone. <p><i>Objectives – Rustain Morgan:</i></p> <ul style="list-style-type: none"> Identify common CT appearance of benign FDG avid processes. Describe locations of likely metastatic disease for various malignancies and their associated CT findings. Apply the knowledge obtained to increase confidence when examining a study. <p>PET/CT Study Rustain Morgan & Sanjeev Grewal <i>Objectives – Rustain Morgan:</i></p> <ul style="list-style-type: none"> Demonstrate how to utilize CT appearance to narrow a differential. Identify when SPECT should be utilized for further characterization. Differentiate benign vs concerning CT features. <p><i>Objectives – Sanjeev Grewal</i></p> <ul style="list-style-type: none"> Identify the type of Artifact seen in this case study. Consider the importance of communication between the patient and technologist. Discuss the importance of communicating effectively with the Radiologist.
<p>1445-1500</p>	<p>REFRESHMENT BREAK</p>	<p>Salon 1 & Stanley Park Foyer</p>
<p>1500-1630</p>	<p>SESSION 7 – MEDICAL ISOTOPES SUPPLY in 2018 and BEYOND Chairs: Heather Hughes/Andrew Ross</p>	<p>Salons 2 & 3</p>
	<p>1500-1530</p> <p>1530-1600</p> <p>1600-1630</p>	<p>GMP Harmonization Andrew Ross <i>Objectives:</i></p> <ul style="list-style-type: none"> Identify the national and international challenges facing the approval of radio-pharmaceuticals Discuss the current initiatives undertaken for the harmonization of GMPs <p>Over View of the Global Tc-99m Supply Situation-The Supply and Demand Equation Now and in the Future François Couillard <i>Objectives:</i></p> <ul style="list-style-type: none"> Provide an up-to-date overview of the global Tc-99m supply and demand situation. Assess the likelihood of future Tc-99m product shortage. Review the status of new Tc-99m / Mo-99 production facilities and likely barriers to entry. <p>Forum Discussion</p>
<p>1630</p>	<p>Closure</p>	

SCIENTIFIC COMMITTEE - 2018

Drs. Jean-Luc Urbain & Philip Cohen, co-chairs (CANM)

Ms. Karren Fader & Ms. Louise Rimanic, co-chairs (CAMRT)

Dr. Khun Visith Keu
Dr. Denise Chan
Dr. Salem Yuoness
Dr. Jonathan Abele

***This activity has been made possible thanks to the educational support of the following sponsors:
La tenue de cette activité a été rendue possible grâce à une subvention à visée éducative de:***

PLATINUM:

Jubilant Draximage

GOLD:

Cyclomedica

Isologic

Lantheus Medical Imaging

SILVER:

Bayer Healthcare

GE Healthcare

Hermes

Siemens Healthineers

BRONZE:

Advanced Accelerator Applications

Canada (AAA)

Curium

Philips

Servier

OTHER:

Rotem

***A special thanks to the following exhibitors:
Nous tenons à remercier les exposants suivants :***

Advanced Accelerator Applications Canada Inc.

Bayer Healthcare

Bruker Biospin

BTG International Canada Inc.

Canadian Association of Medical Radiation

Technologist

Curium

Cyclomedica Canada Limited

GE Healthcare Canada Inc.

Hermes Medical Solutions Canada Inc.

Isologic Radiopharmaceutiques

IsoSolutions Marketing & Management Inc.

Jubilant DraxImage Inc.

Lantheus Medical Imaging

MIM Software Inc.

Philips Healthcare

Segami Corporation

Servier Canada

Siemens Canada

Trasis

VISIT OUR WEBSITE

For information, please visit our Website at: <https://www.canm-acmn.ca>
